1 completed. .
Follow IMPULS Endowment Fund: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Czech Pharmaco-epidemiological Study on Disease Modifying Drugs interferons, glatiramer acetate, teriflunomide, dimethyl fumarate, alemtuzumab, cladribine, fingolimod, ponesimod, rituximab, ocrelizumab, ofatumumab, natalizumab - Multiple Sclerosis | Completed | IMPULS Endowment Fund | 17478 | 2019-01-01 | 2023-03-09 |
Alemtuzumab (1) · Cladribine (1) · Dimethyl Fumarate (1) · Fingolimod Hydrochloride (1) · Glatiramer Acetate (1) · Interferons (1) · Natalizumab (1) · Rituximab (1) · ocrelizumab (1) · ofatumumab (1) · ponesimod (1) · teriflunomide (1)
Czechia (1)